Rykindo extended-release microspheres NDC 72526-102

NDC codes

FDA NDC Directory

Product NDC (as listed)72526-102Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72526-0102Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72526-102-11	72526010211	1 KIT in 1 KIT (72526-102-11) * 2 mL in 1 VIAL, SINGLE-DOSE (72526-202-01) * 2 mL in 1 SYRINGE, GLASS (72526-801-01)Marketed from Jun 20, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Rykindo extended-release microspheresSuffix: extended-release microspheres
Generic name (nonproprietary): risperidone
Dosage form: Kit
Labeler: Shandong Luye Pharmaceutical Co., Ltd.
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 212849
Marketing start: Jun 20, 2023
Listing expires: Dec 31, 2027
Identifiers: Product ID 72526-102_4701fbbb-2d07-4b47-9596-4255a49c7dbcSPL ID 4701fbbb-2d07-4b47-9596-4255a49c7dbcSPL set ID 58534c96-96f5-4c2e-a061-92d4506aee91RxCUI 402010, 402011, 402012, 2639734, 2639736, 2639738

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

NDC on a medical claim

N472526010211 followed by a unit qualifier and the quantity

Package 72526-0102-11. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective May 26, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

RYKINDO is indicated: for the treatment of schizophrenia in adults as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults RYKINDO is an atypical antipsychotic indicated: for the treatment of schizophrenia in adults. ( 1 ) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 212849

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 212849
Product	Strength	Form · route	Labeler	Product NDC
Rykindo extended-release microspheresrisperidone	—	Kit	Shandong Luye Pharmaceutical Co., Ltd.	72526-103
Rykindo extended-release microspheresrisperidone	—	Kit	Shandong Luye Pharmaceutical Co., Ltd.	72526-104